A Parallel-Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Brief description of study

If you have been diagnosed with advanced prostate cancer with high levels of DickkopM (DKK1), you may qualify for this Phase 1b/2a study investigating the DKK1 inhibitor, DKN-01, administered alone or in combination with docetaxel. The main purpose of this study is to determine the safety and effectiveness of DKN-01 as a new immunotherapy for treating advanced prostate cancer.

Clinical Study Identifier: s17-01747
ClinicalTrials.gov Identifier: NCT03837353
Principal Investigator: David R. Wise.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.